Objectives. Patients diagnosed with RA have an increased risk of some cancers. However, limited data are available on the important issue of prognosis of RA patients with cancer.
Introduction
RA is a common autoimmune disease, with an estimated population prevalence of 1% in industrialized countries [1] . Synovial joints are particularly affected by dysregulated lymphocytes reacting against self-antigens [1, 2] . RA cannot be cured, but many different types of treatments can alleviate symptoms and/or modify the disease process. Since dysregulation of the host's immune surveillance is a recognized cause of human cancer, the subsequent risk of malignancy after diagnosis of RA has been studied extensively [3, 4] . Lymphoma risk has been consistently elevated in RA patients. In addition, an increased risk of non-melanoma skin, lung and prostate cancers has also been noted [58] , whereas a decreased risk has been noted for colon, rectal and endometrial cancers [8] .
To our knowledge, limited studies have been carried out on the influence of RA on prognosis of cancer patients [911] . However, such data would be important for a disease as common as RA. Such data would also have ramifications into the possible shared immunological mechanisms of RA and cancer survival. In the present study, we used the nationwide Swedish data resources to investigate the prognosis among cancer patients with RA compared with those without RA. The present report is based on 6309 cancer patients with a previous hospitalization of RA.
Patients and methods
We used the Swedish Hospital Discharge Register, founded in 196465 by the National Board of Health and Welfare with a complete nationwide coverage since 1987, to create a cohort of RA patients [12, 13] . RA patients were retrieved according to the 7th (196468), 8th (196986), 9th (198796) and 10th (1997 to date) International Classification of Diseases codes. These RA patients were linked to the National Swedish Cancer Registry [14] , founded in 1958 with close to 100% coverage, to identify all incident cancers 1 year after the hospitalization of RA until 31 December 2006; a total of 6309 cancer patients were identified in our database with a previous hospitalization of RA. The Cancer Registry used a four-digit code according to ICD7 to identify malignant tumours during the study period. Additional linkages were carried out to national census data to obtain individual socio-economic status, National Registry of Causes of Death to identify date of death, and the Emigration Registry to identify date of emigration. All linkages were performed by the use of an individual national identification number that is assigned to each person in Sweden for their lifetime. This number was replaced by a serial number for each person in order to provide anonymity.
Tumour depth of invasion, nodal status and presence of metastatic disease have been available since 2002 according to the tumor-node-metastasis (TNM) system introduced by the American Joint Committee on Cancer [15] . T describes how far the primary tumour has grown into the wall of the intestine and whether it has grown into nearby tissues; N gives the extent of spread to nearby (regional) lymph nodes; and M indicates whether the cancer has spread (metastasized) to other organs of the body. Numbers or letters appearing after T, N and M provide more details about each of these factors. The numbers 0 through 4 indicate increasing severity.
Follow-up for survival began at diagnosis of cancer and terminated at death, emigration or the closing date of the study (31 December 2006), whichever came first [16] . Cox's proportional hazard regression models were used to estimate the hazard ratios (HRs) for disease-specific and overall survival. HR indicates the relative risk of dying in the defined period compared with a reference group; when it is >1.0, the risk is higher than in the reference group. HRs were adjusted for age at diagnosis, sex, period, socio-economic status, diagnosis region and hospitalization of chronic obstructive pulmonary diseases (a proxy of smoking). For the analysis of disease-specific survival, death as a result of specific cancer (recorded as underlying cause of death) was the primary end point; deaths due to other causes were censored. For the analysis of overall survival, death due to any cause was the end point. The proportional hazard assumption for the covariates was tested by Schoenfeld residuals and by plotting the log of the negative log of the survival function vs the log of time; covariates were stratified in the models if they did not meet the assumption. All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC, USA). The ethics committee at Lund University, Sweden, approved this study.
Results
A total of 1 411 163 cancer patients were identified in the database from 1961 to 2006, and among them 6309 patients had a previous hospitalization of RA (Table 1) . Prostate, lung and breast cancers were the most common cancer sites. The median age at diagnosis of cancer was 69 years for patients without RA, and 73 years for those with RA. For specific cancer sites, cancer patients with RA were, on average, older than those without RA, with an exception of prostate cancer. The largest age difference was noted for Hodgkin's disease. Male patients (51%) outnumbered female patients (49%).
Compared with all cancer patients without RA (Table 2 ), cancer patients with RA had a worse prognosis, with HRs of 1.29 (95% CI 1.26, 1.33) and 1.31 (95% CI 1.28, 1.35) for cause-specific and overall survival, respectively. For specific cancer sites, skin squamous cell carcinoma patients with RA had the worst survival (HR 1.88; 95%CI 1.01, 3.50 and HR 1.87; 95% CI 1.63, 2.15 for causespecific and overall survival, respectively). Patients with cancers of the upper aerodigestive tract, small intestine, colorectum, liver and breast, and with non-Hodgkin's lymphoma and leukaemia, had an increased risk of dying of these specific cancers compared with those without RA. For dying of overall causes, all cancer patients with RA showed a worse prognosis, with an exception of gastric, small intestinal, liver, pancreatic, thyroid gland and connective tissue cancers. To examine the treatment effect, the HRs were calculated separately for patients hospitalized with RA 14 and 55 years before the diagnosis of cancer; the results were similar between the two groups (data not shown).
Since the diagnostic age was different among cancer patients with and without RA, we further stratified the analyses by age at diagnosis (data not shown), using patients without RA in the same age groups as reference. The overall HRs were 1.26 (95% CI 1.19, 1.34), 1.39 (95% CI 1.33, 1.45) and 1.32 (95% CI 1.27, 1.37) for patients diagnosed at <65, 6574 and 575 years of age, respectively. For specific cancer sites, HRs showed variation for different diagnostic age and some of the HR was not significant in specific age group because the cases were decreased by stratifying. For breast, endometrial, bladder and skin (squamous cell carcinoma) cancers and for nonHodgkin's lymphoma, HRs were significant for all the age groups.
The stage of a cancer measures how far the cancer has spread, and it is a strong prognostic indicator of cancer prognosis. In Table 3 , we compared tumour characteristics among cancer patients with and without RA. Since the TNM staging system was recorded since 2002, the number of cancer cases with TNM information was small for most sites; thus, we listed the data only for the common cancer sites, including breast, colon and prostate cancers. There were no differences of TNM classes among cancer patients with or without RA. Cancer patients may be diagnosed at an earlier stage and younger age because of medical surveillance after diagnosis of RA, leading to better survival. For prostate cancer, we examined the distribution of patients with T1c, an indicator of prostate-specific antigen (PSA) screening, to see if these patients were diagnosed at an earlier stage in different age groups, and no difference was noted among patients with and without RA (P = 0.50).
Discussion
In this population-based study, 6309 cancer patients were identified with a previous hospitalization of RA, and they were followed up until year 2006. Compared with cancer patients without RA, those with RA experienced a significantly increased risk of dying of specific cancer and overall causes, ranging from 1.15 to 1.88 for different types of cancer. The worse prognosis was unlikely to be related to tumour stage, which showed no differences among RA patients and controls among common cancers. Similarly, age difference at diagnosis among patients with and without RA did not explain the survival difference because this variable was controlled for in the analysis and because the difference remained in the specific age-stratified analysis. The effect of surveillance bias could be minimal because the distribution of prostate cancer with T1c by age was not different among patients with and without RA.
The data quality in this study is high because it is based on the nationwide databases with medically diagnosed cancers and RA, registered underlying causes of death and completed follow-up of cancer patients, guaranteeing reliable data. The analysis of hospitalized RA patients is an advantage as far as diagnostic accuracy, but a disadvantage as far as excluding RA patients not hospitalized. These questions were extensively discussed in our previous paper that summarized diagnostic accuracy as 90% and sensitivity (i.e. proportion of RA patients hospitalized) as 75% [17] . The high hospitalization rate for RA (75%) in Sweden leads to less selection bias, although patients hospitalized for RA may represent severe clientele, and the data from this study are not directly applicable to all patients with RA. Another limitation is the lack of information on cancer medication, treatment and other individualrelated factors. For example, smoking is a risk factor for RA and it may be related to cancer survival. We had no data on smoking, but we used hospitalization for chronic obstructive pulmonary diseases as a proxy for smoking [18, 19] . In addition, because of multiple comparisons, some findings may be due to chance. An approach to deal with this problem is to adjust the CIs to the number of comparisons, but there is no agreement on how the adjustment should be made. In this study, we will emphasize the value of high HRs and 95% CIs extensively deviating from the borderline value of 1.00, together with biological plausibility and agreement with previous hypotheses and results, all of which will be evoked in the discussion below. Only a few previous studies have investigated the influence of RA on the survival of cancer patients and most of the previous studies were based on small number of cases, leading to inconsistent results. A study from UK showed that the risk of death was significantly increased among cancer patients with RA compared with those without RA [20] , with an HR of 1.4, which was in line with our results. However, the risk of death could not be further examined for specific cancer sites in that study because the number of cancers at the individual sites was too small. Another study showed that non-Hodgkin's lymphoma patients with RA had similar overall survival compared with those without RA, but RA patients were at a lower risk of dying of lymphoma [9] , which was inconsistent with our study showing worse survival in non-Hodgkin's lymphoma patients with RA. The difference may be due to the adjustment of multiple variables in the previous study, including prognostic index score and lymphoma grade, and the difference of identifying RA. The prognosis among RA patients with lung and kidney cancers was inconsistent in previous studies [10, 11] . Abasolo et al. [10] reported that RA patients with lung or kidney cancer have higher mortality than expected, which was inconsistent with our data. However, their study was based on nine lung cancers and two kidney cancers, suggesting that their findings may be due to chance. Although the incidence of colon cancer in patient with RA was decreased, the prognosis for colon patient with RA was worse compared with those without RA.
The mechanistic rationale for studying cancer survival in RA patients is the assumption that any comorbidity may be a disadvantage. Moreover, RA patients have a high risk of developing other comorbid conditions, including cardiovascular diseases (CVDs) and other autoimmune diseases [2123] . To study the effect of comorbidities, other underlying causes of death were also examined. The risk of dying of chronic ischaemic heart disease (5.1% in patients with RA and 4.8% in those without RA) and heart failure (3.0 vs 2.4%) was higher in RA patients compared with those without RA, but only the difference for heart failure was statistically significant. Our data suggested that RA patients may have an increased risk of developing heart failure, which may contribute to the observed worse prognosis among RA patients. Besides these common CVD comorbidities, the risk of dying of some specific cancers, such as breast and skin cancers and non-Hodgkin's lymphoma, was also higher among patients with RA, supporting our assumption that cancer in RA patients will decrease their prognosis. Genetic polymorphism of TNF receptor-associated factor1/C5 (TRAF1/C5), which is thought to be an immune-related gene, closely involved in the onset and/ or perpetuation of the inflammatory process, has been shown to be a genetic risk factor for RA [24] . TRAF1 has been shown to be involved in the regulation of antiapoptotic pathways. A recent study suggested that TRAF1/C5 was associated with increased mortality in RA patients, and the association was independent of RA activity and severity [25] . The HLA-DRB1 genotypes could also be related to the increased mortality among cancer patient with RA compared with those without RA [26] .
In this study, we examined the tumour characteristics of TNM classes for common cancers among patients with and without RA and no difference was noted for these cancers, suggesting that the worse prognosis noted for breast, colon and prostate cancers with RA could not be due to advanced staging. Patients were recorded in the TNM classes since 2002 in the Swedish Cancer Registry, which accounted for 10% of all breast cancers and 17% of all prostate cancers. The limited number of cases made the analysis of other uncommon tumours impossible. When patients were hospitalized for RA, they may have more chance to carry out medical examination. For example, the risk of cancer after a few autoimmune diseases was more pronounced in the first year of follow-up compared with the later period [27, 28] . Intensive medical surveillance may lead to the diagnosis of cancer, especially of breast and prostate cancers with screening programme, at an earlier stage or a young age. We had no data about the possibility of taking mammography test in patients with RA. In fact, there were no differences between patients with RA and controls for the distribution of T1c by age (in response to PSA testing) suggesting that medical surveillance in patients with RA could be minimal. Furthermore, age at diagnosis of cancer is an important prognosis indicator, and cancer patients with RA were usually diagnosed at an older age, which may somewhat explain the worse prognosis noted for these patients. However, in our analyses age at the diagnosis of cancer has been adjusted for and the difference remained in the specific age-stratified analysis, suggesting that the age effect could be minimal.
Cancer patients with RA may have weak psychological well-being, and they could receive less aggressive therapy, and possible interruption of treatment due to complications, leading to decreased life expectancy. Unfortunately, information about treatment was not available in our database, which is a limitation of this study. We tried to see the influence of RA treatment on survival by dividing the hospitalization of RA at different times, based on the assumption that patients hospitalized with RA lately may receive more intensive treatment compared with those hospitalized in the past. The results were similar between the two groups (14 and 55 years) suggesting treatment effect could be minimal. In ageing populations, the number of persons with the two diseases will increase greatly, whereby medical doctors will face the challenges of the two diseases. Multidisciplinary treatments may be necessary for these patients to improve survival, as similar approach has been introduced to patients with diabetes and cancer to improve their prognosis [29] .
In summary, cancer patients with a previous hospitalization of RA had a worse prognosis compared with those without RA, and the high mortality could be independent of age at diagnosis and tumour staging. The worse prognosis was noted for most of the cancer sites, and these patients will need a different, multidisciplinary treatment approach in order to achieve better survival rates.
Rheumatology key messages
. Cancer patients with RA had a worse prognosis.
. The worse prognosis in cancer patients with RA was independent of tumour staging.
